Achieves a High Disease Control Rate in Head and Neck BCC with Vismodegib-RT Regimen.

Published Date: 04 Mar 2024

After a year in a small prospective trial, 91% of cases had local control.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training

2.

More Data Back Teclistamab for Autoimmune Disease

3.

Many women undergo annual mammography, despite biennial screening recommendations

4.

For the first time in humans, a chemotherapy drug reaches the brain.

5.

A retrospective study examined the role of CA 19-9 and CEA in duodenal adenocarcinoma prognosis.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot